Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021

We estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against any COVID-19 infection among individuals ≥45 years in Chennai, Tamil Nadu, India. A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai. The esti...

Full description

Saved in:

Bibliographic Details
Published in:	Vaccines (Basel) Vol. 10; no. 6; p. 970
Main Authors:	Murali, Sharan, Sakthivel, Manikandanesan, Pattabi, Kamaraj, Venkatasamy, Vettrichelvan, Thangaraj, Jeromie Wesley Vivian, Shete, Anita, Varghese, Alby John, Arjun, Jaganathan, Kumar, Chethrapilly Purushothaman Girish, Yadav, Pragya D, Sahay, Rima, Majumdar, Triparna, Dudhmal, Manisha, Sivalingam, Azhagendran, Dhanapal, Sudha Rani, Durai Samy, Augustine, Radhakrishnan, Vijayaprabha, Muni Krishnaiah, Murali Mohan, Arunachalam, Suresh, Gandhi, Punita Muni Krishna, Govindasamy, Elavarasu, Chinnappan, Prabhakaran, Sekar, Dhana Priya Vadhani, Marappan, Prakash, Pounraj, Ezhil, Ganeshkumar, Parasuraman, Jagadeesan, Murugesan, Narnaware, Manish, Bedi, Gagandeep Singh, Kaur, Prabhdeep, Murhekar, Manoj
Format:	Journal Article
Language:	English
Published:	Basel MDPI AG 17-06-2022 MDPI
Subjects:	Age AZD 1222 ChAdOx1 nCoV-19 Coronaviruses COVID-19 COVID-19 vaccines Covishield Genomic analysis Households Immunization SARS-CoV-2 inactivated vaccines Severe acute respiratory syndrome coronavirus 2 vaccine effectiveness Vaccines Viral diseases Tamil Nadu India India
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against any COVID-19 infection among individuals ≥45 years in Chennai, Tamil Nadu, India. A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai. The estimated sample size was 10,232. We enrolled 69,435 individuals, of which 21,793 were above 45 years. Two-dose coverage of Covishield in the 18+ and 45+ age group was 18% and 31%, respectively. Genomic analysis of 74 out of the 90 aliquots collected from the 303 COVID-19-positive individuals in the 45+ age group showed delta variants and their sub-lineages. The vaccine’s effectiveness against COVID-19 disease in the ≥45 age group was 61.3% (95% CI: 43.6–73.4) at least 2 weeks after receiving the second dose of Covishield. We demonstrated the effectiveness of two doses of the ChAdOx1 vaccine against the delta variant in the general population of Chennai. We recommend similar future studies considering emerging variants and newer vaccines. Two-dose vaccine coverage could be ensured to protect against COVID-19 infection.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work.
ISSN:	2076-393X 2076-393X
DOI:	10.3390/vaccines10060970